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Twelve patients were treated with omadacycline (OMC) as part of 
a multidrug regimen for Mycobacterium abscessus. The majority 
of infections were of pulmonary origin (7/12; 58.3%). The median 
(interquartile range) duration of OMC was 6.2 (4.2–11.0) months. 
Clinical success occurred in 9/12 (75.0%) patients. Three patients 
experienced a possible adverse effect while on therapy.
Keywords.  Mycobacterium abscessus; omadacycline; 
rapidly growing nontuberculous mycobacteria.
Nontuberculous mycobacteria (NTM) are opportun-
istic pathogens that are intrinsically resistant to many 
antimicrobials and lead to significant health care costs, mor-
bidity, and mortality [1]. Specifically, Mycobacterium abscessus 
complex (composed of the subspecies M. abscessus, M. bolletii, 
and M. massiliense) is the most drug-resistant and pathogenic 
of the rapidly growing mycobacteria (RGM) and is very chal-
lenging to treat, partly owing to the varying resistance mech-
anisms between these subspecies (including to macrolides, 
an important therapeutic for NTM treatment, if susceptible, 
and also available in an oral formulation) and prolonged treat-
ment durations that are typically expensive [2]. Furthermore, 
a lack of clinical trials and minimally effective oral therapies 
lead to variations in how patients are treated and further com-
promise patient satisfaction, respectively [3]. It is crucial that 
novel antibiotics with optimal oral bioavailability, minimal 
adverse effects (AEs), and effectiveness against all subspecies 
of M. abscessus complex be discovered, developed, and clini-
cally evaluated.
Omadacycline (OMC), a semisynthetic aminomethylcycline 
within the tetracycline (TCN) class, is available both in in-
travenous and oral formulations and is Food and Drug 
Administration (FDA) approved for community-acquired 
pneumonia and acute bacterial skin and skin structure infections 
[4]. Recent investigations have shown potent in vitro activity 
of OMC against drug-resistant M.  abscessus complex clinical 
isolates, with observed minimum inhibitory concentration 
(MIC)90 values similar to tigecycline (TGC) and eravacycline 
(ERV; intravenous-only glycylcycline and fluorocycline, respec-
tively, within the TCN class) [5, 6]. However, limited studies 
have reported patient outcomes of those treated with OMC for 
M. abscessus infections [7]. The objective of this case series was 
to describe preliminary real-world experience of OMC for the 
treatment of M. abscessus infections.
METHODS
This was a multicenter, retrospective, observational case series 
at 6 geographically distinct medical centers in the United States 
in which OMC was initiated between January and August 2020. 
We included individuals aged ≥18 years with ≥1 M. abscessus–
positive culture, in the setting of clinical suspicion for either 
pulmonary or extrapulmonary infection, who received OMC 
for ≥3 months with ≥3 months of documented NTM follow-up 
after OMC initiation. Patients were still included if negative 
circumstances (eg, OMC discontinued due to AE, death) pre-
cluded insufficient exposure or duration (<3 months) of OMC 
continuation and/or follow-up.
Early clinical success was defined as a composite of sur-
vival, lack of clinical/radiographic worsening, lack of alteration 
of OMC therapy due to concerns for treatment failure, lack of 
microbiologic relapse (if patient has achieved culture conver-
sion or microbiologic clearance and cultures were drawn), and 
lack of culture persistence for 3 consecutive positive cultures 
following OMC initiation (if patient has not had at least 2 neg-
ative cultures and cultures were drawn), which was evaluated 
throughout the required follow-up. We also reported intentions 
for OMC utilization and incidence of AE.
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Microbiologic relapse was defined as 2 consecutive cultures 
positive for the same pathogen isolated from index culture fol-
lowing sputum culture conversion (respiratory) or microbio-
logic clearance (nonrespiratory). Sputum culture conversion 
was defined as having at least 3 consecutive negative sputum 
NTM cultures over 12  months. Microbiologic clearance was 
defined as having any negative culture following positive 
index culture (nonrespiratory). The Clinical and Laboratory 
Standards Institute (CLSI) susceptibility breakpoints were 
applied, when applicable, for interpretation of MIC values, 
while the FDA antibacterial susceptibility interpretive criteria 
were used when information was not available via CLSI [8, 
9]. Combination therapy was defined as any antibiotic used in 
tandem with OMC for ≥28 days. All adverse effects while on 
OMC were reported, although they could not be fully attrib-
uted to OMC due to combination regimens. Descriptive statis-
tics were utilized for analysis using IBM SPSS software, version 
26.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
Overall, 12 patients met inclusion criteria. Four individuals 
were excluded due to insufficient exposure to OMC (3/4) and/
or insufficient duration of follow-up (4/4). Included individ-
uals had a median age (interquartile range [IQR]) of 58 (54–63) 
years, they had a median body mass index (IQR) of 23.6 (21.1–
28.9) kg/m2, 50.0% were female, and 91.7% were Caucasian. 
Common comorbidities in those with nontuberculous myco-
bacterial pulmonary disease (NTM-PD) included interstitial 
lung disease (5/7; 71.4%), chronic obstructive pulmonary dis-
ease (2/7; 28.6%), asthma (2/7; 28.6%), and solid organ ma-
lignancy and/or acute myeloid leukemia (2/7; 28.6%), while 
no patients had cystic fibrosis or autoimmune disease. The 
majority of patients had insurance coverage through private 
entities (6/12; 50.0%), followed by Medicare (3/12; 25.0%; 
evaluated due to insurance coverage associated with selection 
of medications), and were treated with OMC strictly in the out-
patient setting (10/12; 83.3%). Of patients included in this anal-
ysis, 5/12 (41.7%) had surgical interventions (debridement and/
or incision and drainage).
The source of infection was primarily NTM-PD (7/12; 
58.3%), followed by bone/joint (2/12; 16.7%). Three other 
extrapulmonary sites of infection involved an intra-abdominal 
infection, a skin and soft tissue infection, and an infected in-
travenous catheter. Of those with NTM-PD, the radiographic 
pattern was 57.1% (4/7) nodular bronchiectatic and 42.9% 
(3/7) fibrocavitary. Disseminated infection occurred in 2/12 
(16.7%) of patients. The initial M. abscessus isolates were most 
commonly isolated from expectorated sputum (4/12; 33.3%), 
wound/tissue (4/12; 33.3%), or induced sputum (1/12; 8.3%). 
Of all included cases, 7/12 (58.3%) of isolates underwent 
subspeciation (6/7; 85.7% subspecies M. abscessus, 1/7; 14.3% 
subspecies M.  massiliense). Erm gene genotyping (genes that 
can express inducible macrolide resistance) was conducted in 
9/12 (75.0%) isolates, with functional erm gene detected in 6/9 
(66.7%) [2].
Before OMC initiation, antibiotic therapy was administered 
in 10/12 (83.3%) cases, for a median (IQR) of 4.7 (3.4–12.7) 
months (these data were calculated based on 11 patients, as data 
were not available for 1 patient). Mycobacterial cultures were 
positive at the time of OMC initiation in 6/9 (66.7%) patients 
for whom this information was known. Only a single isolate 
underwent MIC determination for OMC, which was 0.5 mcg/
mL. However, TIG MICs were reported for 11/12 (91.7%) iso-
lates (range, 0.06–1 mcg/mL; MIC90, 1 mcg/mL). MIC values for 
other antibiotics are reported in Supplementary Table 1.
The total median duration of OMC (IQR) was 6.2 (4.2–11.0) 
months, with the median duration of follow-up post-OMC initi-
ation (IQR) being 5.1 (3.4–7.2) months. All patients received ≥2 
companion antibiotics, with the most common being amikacin 
(8/12; 66.7%), imipenem (5/12; 41.7%), linezolid/tedizolid 
(5/12; 41.7%), azithromycin (4/12; 33.3%), and/or clofazimine 
(4/12; 33.3%). Interestingly, 2 patients received TIG concomi-
tantly with OMC. Oral therapy was strictly utilized in all cases, 
with a loading dose of 450 mg once daily on days 1 and 2 used 
for initiation of therapy in 2/12 (16.7%) patients, while most pa-
tients did not receive a loading dose on initiation and received a 
maintenance dose of 300 mg once daily (10/12; 83.3%).
Clinical success occurred in 9/12 (75.0%) cases. Failures in-
volved 3 cases with radiographic fibrocavitary and nodular 
bronchiectatic (plus dissemination) sources and skin and soft 
tissue sources. Other clinical and composite end point charac-
teristics can be found in Table 1. The primary reasons for OMC 
utilization were related to antimicrobial resistance to previous 
antibiotic(s) (8/12; 66.7%), previous antibiotic failure (6/12; 
50.0%), ease of administration (6/12; 50.0%), and oral bioavail-
ability of OMC (6/12; 50.0%).
Three patients experienced an AE while on therapy. One pa-
tient experienced a gastrointestinal AE (nausea/vomiting/diar-
rhea), and the OMC dose was reduced from 300  mg daily to 
150 mg twice daily, with improvement in symptoms. Another 
patient experienced serum creatinine increase ≥0.5  mg/dL; 
OMC was temporarily discontinued, and this AE resolved. The 
third patient experienced AST/ALT elevations >3× the upper 
limit of normal; OMC was continued, despite these laboratory 
abnormalities, and the abnormalities resolved.
DISCUSSION
We report the largest real-world, observational, multicenter 
description of early treatment outcomes for patients treated 
with OMC for pulmonary and extrapulmonary M.  abscessus 
infections with promising results. Due to the in vitro activity of 
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it is expected that the medical community would have elevated 
curiosity about the use of OMC for patients with M. abscessus. 
Our results show similar (or slightly higher) preliminary re-
sults congruent with smaller reports of OMC and with other 
agent(s) used for M. abscessus infections, both in index and re-
fractory disease [7, 10, 11]. Although the OMC treatment in 
its entirety was not included (as treatment is still ongoing for 
the majority of cases), no NTM-treating clinician discontinued 
OMC due to concerns of failure, with a current median OMC 
duration of 6.2 months. Furthermore, incidence rates of pos-
sible AEs due to OMC were relatively similar to those in the 
phase 3 trials for OMC and other real-world analyses of novel 
tetracyclines, despite much longer durations of exposure in this 
case series [12, 13].
An important therapeutic for NTM infections is macrolides 
(if susceptible), which are subject to inducible resistance 
via the erm gene and prolongation of the QTc interval [14]. 
Importantly, OMC is not impacted by functional erm gene ex-
pression and has not been shown to cause clinically significant 
QTc prolongation. Given the lack of some clinical laboratories 
performing subspeciation or erm gene detection (highlighted 
in this analysis with conduction in 58.3% and 75.0%, respec-
tively), OMC could provide a viable oral alternative option for 
those clinicians and sites without the complete microbiological 
picture.
Tigecycline and ERV have demonstrated similar in vitro ac-
tivity against isolates of M. abscessus; however, both antibiotics 
are only available in intravenous formulations and are dosed 
twice daily, which is not ideal for prolonged treatment courses, 
and are associated with significant gastrointestinal AEs. OMC 
is dosed once daily and has shown fewer gastrointestinal AEs 
than TIG or ERV (8.3% in this analysis). Importantly, reported 
MIC90 values of ERV against M.  abscessus (1 mcg/mL) are 
higher than the current FDA breakpoint for Enterobacterales, 
while reported MIC90 values for OMC against M. abscessus have 
been reported to be 2-fold lower than their current FDA break-
point [5, 9].
This report has obvious limitations. First, this was a retro-
spective, observational case series with a small number of pa-
tients and the possibility of selection bias. Inclusion criteria 
for our analysis required relatively short durations of OMC 
exposure and follow-up (≥3  months) relative to traditional 
treatment durations associated with M.  abscessus; therefore, 
although the median duration of OMC was 6.2  months, the 
duration of OMC exposure as it relates to outcomes may 
have been inadequate to detect a more (or less) favorable re-
sponse. We included both pulmonary and extrapulmonary 
cases of NTM infection, the outcomes of which may be dif-
ficult to compare directly based on potential differences in 
nonpharmacological management (eg, removal of device in 
extrapulmonary cases). Also, subspeciation and functional 
erm gene detection were not available in all cases. However, 
given the rarity of this disease, these data reflect pragmatic 
outcomes that can be useful for clinicians with limited to no 
options for M. abscessus treatment, even without the full mi-
crobiologic picture. Next, all patients were on ≥2 additional 
antimicrobials; therefore, analysis of the direct response 
of OMC is difficult. However, this is also the case with any 
antimicrobial used within a combination regimen. Given the 
multicenter analysis of our study and the complexities of per-
forming in vitro susceptibility with novel antimicrobials, we 
were unable to perform MIC testing for OMC on the majority 
of the clinical M. abscessus isolates to determine initial suscep-
tibility, and the possibility of development of OMC resistance 
while on therapy remains.
Despite these limitations, this is the largest real-world obser-
vational description reporting the experience of early treatment 
with OMC for M.  abscessus within multiple infectious sites. 
A  ≥3-month follow-up evaluating OMC therapy by NTM-
treating clinicians was required for inclusion in this analysis, 
which is a strength compared with other retrospective obser-
vational studies. Also, OMC was studied in some patients who 
had been treated with numerous antibiotics without success 
over long intervals of time. Finally, although MICs for OMC 
were only reported in 8.3% of isolates, MICs for TIG were re-
ported in 91.7% of isolates, and previous reports have shown a 
high correlation between the 2 antibiotics for M. abscessus [5, 
6]. While these early experiences with OMC for M. abscessus 
are important to document, prospective studies and larger real-
world analyses are urgently needed for these difficult-to-treat 
infections.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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